ArticleACS medicinal chemistry letters2026
Multiscale Explainable Machine Learning Reveals Descriptor-Invariant Molecular Determinants of Small-Molecule PD-1/PD-L1 Inhibition.
Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PD-1/PD-L1 immune checkpoint pathway is a major target in cancer immunotherapy; however, small-molecule inhibitor development remains challenging due to the hydrophobic, structurally shallow PD-L1 interface. We developed an explainable artificial intelligence (XAI)-based QSAR framework to identify determinants governing PD-1/PD-L1 inhibition. A data set of 844 compounds, represented using MACCS, PubChem, and Mordred descriptors, was modeled using multiple machine learning algorithms with eXtreme Gradient Boosting (XGBoost) and Light Gradient Boosting Machine (LightGBM) models achieving the highest predictive performance. SHapley Additive exPlanations (SHAP) analysis and scaffold enrichment revealed convergence across descriptors, highlighting nitrogen-rich heteroaromatic systems, sulfur-containing motifs, and fused aromatic scaffolds as key determinants of activity. Active compounds occupied a distinct physicochemical space characterized by low molecular weight (MW) and topological polar surface area (TPSA) < 85 Å
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.